Monday, May 21, 2007

New study adds to worries about diabetes drug class

(Reuters) - The news, published in the New England Journal of Medicine, set off a clamor by consumer groups, heart experts and Congress -- some of whom question the safety of all drugs in this class after a number of studies that have shown liver, heart and bone side effects.




Avandia, made by GlaxoSmithKline, is a member of a drug class called thiazolidinediones or glitazones. They affect a gene called PPAR-gamma and help the body use insulin more effectively.


Read more at Reuters.com Business News

No comments: